FTSE MIB
33.812,44 +41,37 (+0,12%) Dow Jones
40.589,34 +654,27 (+1,64%) Nasdaq
17.357,88 +176,16 (+1,03%) Nikkei 225
37.667,41 -202,10 (-0,53%) Petrolio
76,44 -1,84 (-2,35%) Bitcoin EUR
62.585,42 +1.033,97 (+1,68%)
InflaRx N.V. (IFRX)
| Chiusura precedente | 1,5300 |
| Aperto | 1,5100 |
| Denaro | 1,5000 x 100 |
| Domanda | 1,5400 x 100 |
| Min-Max giorno | 1,4600 - 1,5700 |
| Intervallo di 52 settimane | 1,1400 - 4,3000 |
| Volume | |
| Media Volume | 145.175 |
| Capitalizzazione | 90,091M |
| Beta (mensile su 5 anni) | 1,58 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,7600 |
| Prossima data utili | 08 ago 2024 - 12 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 8,01 |
GlobeNewswireInflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)
MAA for vilobelimab was submitted in JulyMAA has been validated by EMA and is now under reviewRegulatory submission based on pivotal data from PANAMO Phase III trialCompany announces attendance at upcoming scientific and investor events JENA, Germany, Aug. 30, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that the Company has submitted a Marketing Authorization Application (
- GlobeNewswire
InflaRx Reports Second Quarter 2023 Financial Results & Operating Update
• Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the United States • Oral C5aR inhibitor INF904 progressing in single ascending dose (SAD) and multiple ascending dose (MAD) Phase I trial • Progress in clinical development of vilobelimab in other indications, including cutaneous squamous cell carcinoma (cSCC) and pyoderma gangrenosum (PG) • Strong addition to management team as Camilla Chong, M.D., joins as Chief Medical Officer • Ca
